The mechanism of action of anti-PD-1 and anti-CTLA-4 MAbs is to release inhibition on CD4 or CD8 T lymphocytes, which recognize tumor-derived peptides restrictively presented in the context of human leukocyte antigen (HLA) molecules. This evidence concerns the gene CTLA4 and neoplasm.